oxazoles has been researched along with daptomycin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grucz, RG; Hershberger, E; Moldovan, T; Rybak, MJ | 1 |
| Goering, RV; Thomson, KS | 1 |
| Basuino, L; Chambers, HF; Chan, LC; Dip, EC | 1 |
| Barber, KE; Raut, A; Rybak, MJ; Smith, JR | 1 |
| Arber, M; Barata, T; Eales, J; Fleetwood, K; Glanville, J; Gould, IM; Kauf, TL; McCool, R | 1 |
| Alvarez, DN; Bayer, AS; Farah, S; Garcia-de-la-Maria, C; Miro, JM; Mishra, NN; Sakoulas, G; Zapata, B | 1 |
| Blanco, MJ | 1 |
1 review(s) available for oxazoles and daptomycin
| Article | Year |
|---|---|
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
Topics: Anti-Bacterial Agents; Bayes Theorem; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Oxazolidinones; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2017 |
6 other study(ies) available for oxazoles and daptomycin
| Article | Year |
|---|---|
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Topics: Acetamides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Multiple; Enterococcus; Linezolid; Microbial Sensitivity Tests; Oxazoles; Oxazolidinones; Staphylococcus; Time Factors; Vancomycin; Virginiamycin | 2000 |
Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.
Topics: Anti-Bacterial Agents; Daptomycin; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Organophosphates; Oxazoles; Staphylococcal Infections; Tigecycline | 2013 |
Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.
Topics: Animals; Anti-Bacterial Agents; Daptomycin; Drug Administration Schedule; Endocarditis; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Organophosphates; Oxazoles; Rabbits; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2015 |
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Topics: Anti-Bacterial Agents; Daptomycin; Drug Resistance, Bacterial; Enterococcus; Enterococcus faecalis; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Linezolid; Microbial Sensitivity Tests; Organophosphates; Oxazoles; Staphylococcus aureus; Vancomycin | 2016 |
Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Combinations; Drug Resistance, Bacterial; Gentamicins; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Organophosphates; Oxazoles; Rifampin; Streptococcus mitis; Streptococcus oralis; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Building upon Nature's Framework: Overview of Key Strategies Toward Increasing Drug-Like Properties of Natural Product Cyclopeptides and Macrocycles.
Topics: Anthraquinones; Biological Availability; Biological Products; Chemistry, Pharmaceutical; Cyclosporine; Cyclotides; Daptomycin; Depsipeptides; Drug Design; Drug Discovery; Ethers, Cyclic; Gramicidin; Lipopeptides; Macrocyclic Compounds; Macrolides; omega-Conotoxins; Organophosphorus Compounds; Oxazoles; Peptides; Peptides, Cyclic; Thiazoles; Thiazolidines | 2019 |